Notice to Contributors

Manuscripts should be sent in triplicate (original plus two copies) to the Editor, Dr. Michael Moore. The criteria for acceptance of manuscripts to be published in the British Journal of Cancer are originality and high scientific quality. Manuscripts are not be published in the same form, in any language, without the consent of the Publishers. Papers should be in English. Authors whose mother-tongue is not English are urgently requested to have their manuscripts checked for linguistic correctness before submission.

Manuscripts should be typewritten, double-spaced with a wide margin and on one side of the paper only. They should be accompanied by a title page numbered as 1, bearing title, authors full names, affiliation and addresses; and a summary of not more than 200 words. The author to whom correspondence, proofs and reprint requests are to be sent should be clearly indicated.

Full papers should be divided into sections:
1. Introduction
2. Materials and methods
3. Results
4. Discussion
5. Acknowledgements and References.

Short Communications (~1500 words) should not have the above section headings nor a summary. The Editor reserves the right to make literary corrections.

Titles. These are the most read part of papers. Authors should compose them with great care. They should combine brevity with clarity; the shorter the better, not exceeding 100 letters. Authors should submit their own running title, which must not exceed 50 letters. The top of each page should carry the running title and the name of the first author.

Illustrations should be referred to in the text as "Figures" and be given Arabic numbers. They should be marked on the back with the authors name(s) and the title of the paper. Where there is any possible doubt as to the orientation of an illustration, the top should be indicated by an arrow. Photographs and photomicrographs should be high-quality unmounted glossy prints and should not be retouched. Photomicrographs should be chosen so as to exclude technical artefacts. Clearly contrasted prints are essential for adequate reproduction. Magnification is best indicated by a line representing a defined length, included within the photograph. Colour illustrations will be accepted when found necessary by the Editor, although the author will be expected to contribute to the cost. Diagrams should be on separate sheets; they must be drawn with black Indian ink on white paper or feint-ruled graph paper and should be about twice the size of the final reproduction. Lines should be of sufficient thickness to stand reduction.

Photocopies are unacceptable. Each illustration should be clearly described by a legend; all legends should be grouped on a separate sheet of paper. Lettering on figures should be minimal and should not duplicate the legend.

There should be as few Tables as possible; they should have a title and include only essential data; they should be typewritten on separate sheets and given Roman numbers.

References. Only papers closely related to the author's work should be quoted, and these should be to original papers only. Exhaustive lists should be avoided. References in the text should be made by giving the author's surname, with the year of publication in brackets. When the reference is to a specific part of a book, the page number should also be cited. When reference is made to a work by 3 or more authors, the first name followed by et al. should be used on all occasions. If several papers by the same first author and from the same year are cited, a, b, c, etc. should be added after the year of publication. It is the author's responsibility to check the accuracy of all references before submitting a manuscript. References should be brought together at the end of the paper in alphabetical order, where titles of papers and all authors' names should be given in full (except if there are more than 6 authors, when the first 3 names should be followed by "and x others", x being the actual number). Names of journals should be abbreviated as in the Index Medicus, but with full stops after abbreviations (and after authors' initials), followed by the volume number and the page number, e.g.:

McMANUS, M.J., DOMBROSKE, S.E., PIENKOWSKI, M.M.
& 5 others (1978). Successful transplantation of human
benign breast tumours into the athymic nude mouse
and demonstration of enhanced DNA synthesis

References to books and monographs should appear
as in the following examples:

Lippincott: Philadelphia.

STEVenson, A.C. (1966). Sex chromatin and sex ratio in
man. In Sex Chromatin, p. 405. (Ed. Moore.)
Saunders: Philadelphia.

Abbreviations and units should follow the standards
laid down in Units, Symbols and Abbreviations
published by the Royal Society of Medicine (third

Offprints may be ordered on the form accompanying proofs; 25 will be supplied free of charge.

*Editorial correspondence should be addressed to the Editor, Dr Michael Moore, Paterson Laboratories, Christie Hospital and Holt Radium Institute, Manchester M20 9BX.

†Citation of Conference Proceeding or Meetings
Abstracts should be avoided unless there is no other reference.
Aims and Scope

The British Journal of Cancer will accept papers which contain new information, constitute a distinct contribution to knowledge, and are relevant to the clinical, epidemiological, pathological or molecular aspects of oncology.

The Journal is published monthly on behalf of the Cancer Research Campaign by the Scientific and Medical Division, The Macmillan Press Ltd, Houndmills, Basingstoke, Hampshire RG21 2XS. Telephone: Basingstoke (0256) 29242.

Copyright © 1984 by Cancer Research Campaign. ISSN 0007-0920

Manuscripts plus two copies and all editorial correspondence should be sent to the Editor: Dr. Michael Moore, Paterson Laboratories, Christie Hospital and Holt Radium Institute, Manchester M20 9BX.

Annual subscription: UK £105; USA & Canada $260, Airmail $305; Rest of World £135, Airmail £155; (or equivalent in any other currency). Orders must be accompanied by remittance. Cheques should be made payable to Macmillan Journals and sent to: The Macmillan Press Ltd., Farndon Road, Market Harborough, Leicestershire, LE16 9NR, UK. Where appropriate, subscribers may make payments into UK Post Office Giro Account No. 519 2455. Full details must accompany the payment.

Second class postage permit USPS 689–430.

Postmaster please send address corrections to British Journal of Cancer c/o Expediter of the Printed Word, Ltd. 515 Madison Avenue, New York, NY 10022, USA.

Printed in Great Britain by Bell and Bain Ltd., Glasgow.

Enquiries concerning advertising space or rates should be addressed to: Advertising Department, British Journal of Cancer, Houndmills, Basingstoke, Hampshire RG21 2XS. Telephone: (0256) 29242.

All rights of reproduction are reserved in respect of all papers, articles, illustrations, etc., published in this journal in all countries of the world.

Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by The Macmillan Press Ltd for libraries and other users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service, provided that the base fee of $01.00 per copy, plus 0.10 per page is paid directly to CCC, 21 Congress St., Salem, MA 01970, USA. 0007-0920/84 $1.00 + 0.10

Publisher: Harry Holt

Production & Editorial Services: David Ashcroft

Advertising & Promotion Manager: David Guthrie

Circulation Services: A.L. Clark

Whilst every effort is made by the publishers and editorial board to see that no inaccurate or misleading data, opinion or statement appears in this Journal, they wish to make it clear that the data and opinions appearing in the articles and advertisements herein are the responsibility of the contributor or advertiser concerned. Accordingly, the publishers and the editorial committee and their respective employees, officers and agents accept no liability whatsoever for the consequences of any such inaccurate or misleading data, opinion or statement. Whilst every effort is made to ensure that drug doses and other quantities are presented accurately, readers are advised that new methods and techniques involving drug usage, and described within this Journal, should only be followed in conjunction with the drug manufacturer's own published literature.
TRANSFORMING ras ONCOGENES AND MULTISTAGE CARCINOGENESIS. Balmain, A.

PRODUCTION OF TRANSFORMING GROWTH FACTORS BY PRIMARY HUMAN TUMOUR CELLS. Hamburger, A.W., White, C.P. & Dunn, F.E.

THE VALIDITY OF THE LABELLING INDEX IN TUMOUR STUDIES. Hamilton, E. & Dobbin, J.

STUDIES ON INTERLEUKIN 2 RECEPTOR EXPRESSION AND IL-2 PRODUCTION BY MURINE T CELL LYMPHOMAS. Diamantstein, T., Osawa, H., Graf, L. & Schirrmacher, V.

THE CYTOSTATIC ACTIVITY OF CULTURED KUPFFER CELLS. Pulford, K. & Souhami, R.L.

"CONCOMITANT IMMUNITY" IN MURINE TUMOURS OF NON-DETECTABLE IMMUNOGENICITY. Ruggiero, R.A., Bustuoabad, O.D., Bonfil, R.D., Meiss, R.P. & Pasqualini, C.D.

PLATELET SENSITIVITY TO PROSTACYCLIN IN NORMAL SUBJECTS, AND IN PATIENTS WITH BENIGN AND MALIGNANT TUMOURS OF THE BREAST. Benedetto, C., Zonca, M., Tavella, A.M., Petitti, E., Massobrio, M., Nigam, S. & Slater, T.F.

RECOMBINANT DNA HUMAN INTERFERON ALPHA 2 IN ADVANCED BREAST CANCER - A PHASE 2 TRIAL. Padmanabhan, N., Balkwill, F.R., Bodmer, J.G. & Rubens, R.D.


THE EFFECT OF SYSTEMIC HYPERThERMIA ON MELPHALAN PHARMACOKINETICS IN MICE. Honess, D.J., Donaldson, J., Workman, P. & Bleehen, N.M.

MISONIDAZOLE PROTECTS TUMOUR AND NORMAL TISSUES FROM THE TOXICITY OF ORAL CCNU. Lee, F.Y.F. & Workman, P.

DISAGGREGATION OF HUMAN SOLID TUMOURS BY COMBINED MECHANICAL AND ENZYMATIC METHODS. Engelholm, S.A., Spang-Thomsen, M., Brunner, N., Nohr, I. & Vindelov, L.L.

HETEROGENEITY OF COLORECTAL ADENO-CARCINOMAS EVALUATED BY FLOW CYTOMETRY AND HISTOPATHOLOGY. Quirke, P., Dyson, J.E.D., Dixon, M.F., Bird, C.C. & Joslin, C.A.F.

PANCREATIC CARCINOGENESIS – ENHANCEMENT BY CHOLECYSTOKININ IN THE HAMSTER-NITROSAMINE MODEL. Howatson, A.G. & Carter, D.C.

MALE BREAST CARCINOMA – A REVIEW OF 301 CASES FROM THE CHRISTIE HOSPITAL AND HOLT RADIUM INSTITUTE MANCHESTER. Ribeiro, G.


SELECTIVE KILLING OF CONTAMINATING HUMAN FIBROBLASTS IN EPITHELIAL CULTURES DERIVED FROM COLORECTAL TUMOURS USING AN ANTI Thy-1 ANTIBODY-RICIN CONJUGATE. Paraskeva, C., Buckle, B.G. & Thorpe, P.E.

CHARACTERISATION OF MACROPHAGES INFILTRATING HUMAN MAMMARY CARCINOMAS. Steele, R.J.C., Brown, M. & Eremin, O.

Swann-Morton Surgical Blades

You can recognise a Swann-Morton handle by the distinctive circular pattern.

You can recognise a Swann-Morton scalpel blade by its initial sharpness and durability which is of a uniform maximum high standard.

Swann-Morton produce all of the nine universally accepted scalpel blade shapes together with a further seven developed by request and produced as a result of so many years as a leading world supplier of scalpel blades.

Swann-Morton blades are available in stainless or carbon steel in sterile individual packs or non-sterile in packs of 5.

Swann-Morton Ltd.,
Penn Works, Owerton Green,
Sheffield, S6 2BJ, England. Tel: 0742 344231

SECOND ANNOUNCEMENT

The Second International Conference on the Modulation and Mediation of Cancer by Vitamins and Micronutrients under the sponsorship of the Arizona Cancer Center and the International Society for Nutritional Oncology will be held at the Arizona Health Sciences Center, Tucson, AZ Sunday, February 10, 1985 through Wednesday February 13, 1985.

Dr. Frank L. Meyskens, Jr. (University of Arizona) and Dr. Kedar N. Prasad (University of Colorado) will serve as co-chairmen.

For further information:
Mary Humphrey, Conference Coordinator
Arizona Cancer Center
Tucson, Arizona 85724
(602) 626-6044
ECCO 3

The 3rd European Conference on Clinical Oncology and Cancer Nursing
with International Trade Fair

The ECCO Conferences have grown into a key forum for medical oncologists, cancer surgeons, and radiotherapists from all over Europe. The largest contingent from outside Europe is from the USA. A total of some 3,000 doctors are expected to attend ECCO 3. At the same time about 1,000 nurses will be converging on Stockholm, to attend the 1985 annual Cancer Nursing Conference. This, too, will be merged with ECCO 3.

The ECCO Conference covers the entire multi-disciplinary approach to the clinical cancer spectrum: prevention, basic science, diagnostics, therapy, nursing, nutrition, and psychological aspects.

A special trade fair is being held in conjunction with the conference – at the same premises and during the same hours at the Stockholm International Fairs. The trade fair will feature practical demonstrations of new techniques, methods and equipment within cancer technology.

Three events in one – two conferences and a trade fair – will throw light on virtually every aspect of clinical oncology.

For further information please contact

For the trade fair:
ADFORUM SVERIGE AB
Villagatan 1
S-114 32 STOCKHOLM, SWEDEN.
Phone: +46 8 235 235.
Telex: 17186 adforum s.
Telefax: +46 8 104 194.

For the conference:
Stockholm Convention Bureau
Box 1617
S-111 86 STOCKHOLM, SWEDEN.
Phone: +46 8 23 09 90.
Telex: 11556 congrex.
Telegram: Congrex.

STOCKHOLMSMÄSSAN
Stockholm International Fairs